SAS9: MIS Hits Primetime
The Ninth Annual Symposium for the International Society for the Advance of Spine Surgery (SAS9), held this spring in London, welcomed almost 1,700 attendees, double that of 2008, and most sessions provided a spirit of optimism despite the harsh economic environment. Minimally invasive surgery (MIS) took center stage as applications widen and techniques improve, while facet joint replacement devices and materials to simplify revisions also drew crowds.
You may also be interested in...
While most Wall Street analysts predict that the current economic crisis will have little effect on the spine industry over the long haul, there are storm clouds on the horizon that should put spine product manufacturers on guard. With crackdowns by the Department of Justice tipping over into the spine arena and whistleblower lawsuits regarding surgeon/industry relationships in the news, along with several important bills before Congress designed to change how the business of spine surgery is done, current financial constraints may be only the tip of the iceberg in terms of things to come.
By focusing on an overlooked but critical element of spinal anatomy, the facet joint, Archus is applying established principles of total joint replacement to create a new opportunity in spine, while also expanding the potential opportunities in disc replacement.
With up to $100m from Abingworth and a recent $75m FOPO, CymaBay has runway to await pivotal data in primary biliary cholangitis in 2023 for seladelpar, after the candidate failed in NASH. It sees a significant market opportunity in the second-line setting cornered by Intercept.